LRMR

On February 24, 2026, Larimar shares jumped premarket after the FDA granted Breakthrough Therapy Designation for nomlabofusp, which reduces program risk and aims to accelerate market entry. On May 27, 2026, JP Morgan initiated coverage with an 'Overweight' recommendation, following a 55% stock jump in a month after the FDA's breakthrough therapy status announcement. On June 29, 2026, Larimar Therapeutics hosted an investor event to provide updates on its nomlabofusp program. On July 3, 2026, Pomerantz LLP launched an investigation into Larimar Therapeutics regarding potential securities fraud and unlawful business practices related to clinical trial safety disclosures. On July 6, 2026, independent director Thomas Hamilton purchased approximately 50,000 shares on-market, marking the largest insider purchase in the preceding three months. On July 9, 2026, Larimar Therapeutics announced the submission of the first module of its rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp. On August 4, 2026, the company reported positive longer-term open-label study data for nomlabofusp in its second-quarter 2026 financial and business update, showing a well-characterized safety profile, sustained increases in skin frataxin levels, and continued improvements in key clinical outcome measures, leading to a 3.3% gain in LRMR shares. The company also reiterated that the rolling BLA submission was underway for completion in the second half of 2026, and the dosing of the first patient in a global confirmatory Phase 3 study was expected in Q3 2026.